BRCA1 and ovarian cancer: In fact, the results of the recently published Imagyn050 study showed that ovarian cancer patients with BRCA1/2 gene mutations were insensitive to immunotherapy, suggesting that not all DDR or HRR genes can be considered prognostic factors for immunotherapy (17).